Minimizing chemotherapy-induced peripheral neuropathy: preclinical and clinical development of new perspectives

Poupon, Laura; Kerckhove, Nicolas; Vein, Julie; Lamoine, Sylvain; Authier, Nicolas; Busserolles, Jérôme; Balayssac, David

doi:10.1517/14740338.2015.1056777

Cited by 29 publications

(24 citation statements)

References 97 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It is suggested for clinicians, nurses, and other health professionals treating people with CIPN to use composite measurement outcomes including the full complexity of both positive symptoms (pain, paresthesia, and dysethesia) and negative ones (numbness). [158] Trialing potential treatment options such as aceyl-l-carnitine on patients with numbness and dysthesia might be worthwhile. Discussing, identifying, and suggesting interventions with possible protective benefits for patients such as Vitamin E, B12, and omega 3 fatty acids displays best care.…”

Section: Discussionmentioning

confidence: 99%

New Insights into Potential Prevention and Management Options for Chemotherapy-Induced Peripheral Neuropathy

Schloss

Colosimo

Vitetta

2016

Asia-Pacific Journal of Oncology Nursing

View full text Add to dashboard Cite

Objective:Neurological complications such as chemotherapy-induced peripheral neuropathy (CIPN) and neuropathic pain are frequent side effects of neurotoxic chemotherapy agents. An increasing survival rate and frequent administration of adjuvant chemotherapy treatments involving neurotoxic agents makes it imperative that accurate diagnosis, prevention, and treatment of these neurological complications be implemented.Methods:A consideration was undertaken of the current options regarding protective and treatment interventions for patients undergoing chemotherapy with neurotoxic chemotherapy agent or experience with CIPN. Current knowledge on the mechanism of action has also been identified. The following databases PubMed, the Cochrane Library, Science Direct, Scopus, EMBASE, MEDLINE, CINAHL, CNKI, and Google Scholar were searched for relevant article retrieval.Results:A range of pharmaceutical, nutraceutical, and herbal medicine treatments were identified that either showed efficacy or had some evidence of efficacy. Duloxetine was the most effective pharmaceutical agent for the treatment of CIPN. Vitamin E demonstrated potential for the prevention of cisplatin-IPN. Intravenous glutathione for oxaliplatin, Vitamin B6 for both oxaliplatin and cisplatin, and omega 3 fatty acids for paclitaxel have shown protection for CIPN. Acetyl-L-carnitine may provide some relief as a treatment option. Acupuncture may be of benefit for some patients and Gosha-jinki-gan may be of benefit for protection from adverse effects of oxaliplatin induced peripheral neuropathy.Conclusions:Clinicians and researchers acknowledge that there are numerous challenges involved in understanding, preventing, and treating peripheral neuropathy caused by chemotherapeutic agents. New insights into mechanisms of action from chemotherapy agents may facilitate the development of novel preventative and treatment options, thereby enabling medical staff to better support patients by reducing this debilitating side effect.

show abstract

Section: Discussionmentioning

confidence: 99%

New Insights into Potential Prevention and Management Options for Chemotherapy-Induced Peripheral Neuropathy

Schloss

Colosimo

Vitetta

2016

Asia-Pacific Journal of Oncology Nursing

View full text Add to dashboard Cite

show abstract

“…Therefore, the National Cancer Institute's Symptom Management and Health-Related Quality of Life Steering Committee has announced that CIPN is a priority area of translational research in cancer care [4]. Even the latest literature data clearly indicate that although numerous preventative therapies were tested for their potential utility for CIPN alleviation, this clinical entity currently is still not preventable [41][42][43], and many strategies tested were found to be ineffective (Table 1). Therefore, based on meta-analyses of clinical trials, at present, no drug can be proposed as a gold standard to either prevent CIPN or treat its symptoms, and chemotherapeutic drug dose modification remains the only preventative strategy [41].…”

Section: Available Preventative Therapies For Cipn Caused By Oxaliplatinmentioning

confidence: 99%

Chemotherapy-induced peripheral neuropathy—part 2: focus on the prevention of oxaliplatin-induced neurotoxicity

Sałat

2020

Pharmacol. Rep

View full text Add to dashboard Cite

Background Chemotherapy-induced peripheral neuropathy (CIPN) is regarded as one of the most common dose-limiting adverse effects of several chemotherapeutic agents, such as platinum derivatives (oxaliplatin and cisplatin), taxanes, vinca alkaloids and bortezomib. CIPN affects more than 60% of patients receiving anticancer therapy and although it is a nonfatal condition, it significantly worsens patients' quality of life. The number of analgesic drugs used to relieve pain symptoms in CIPN is very limited and their efficacy in CIPN is significantly lower than that observed in other neuropathic pain types. Importantly, there are currently no recommended options for effective prevention of CIPN, and strong evidence for the utility and clinical efficacy of some previously tested preventive therapies is still limited. Methods The present article is the second one in the two-part series of review articles focused on CIPN. It summarizes the most recent advances in the field of studies on CIPN caused by oxaliplatin, the third-generation platinum-based antitumor drug used to treat colorectal cancer. Pharmacological properties of oxaliplatin, genetic, molecular and clinical features of oxaliplatin-induced neuropathy are discussed. Results Available therapies, as well as results from clinical trials assessing drug candidates for the prevention of oxaliplatininduced neuropathy are summarized. Conclusion Emerging novel chemical structures-potential future preventative pharmacotherapies for CIPN caused by oxaliplatin are reported.

show abstract

“…Up to tenfold higher concentrations were described for systemic chemotherapy as compared to intraperitoneal use, and side effects for most therapies are common 4 . Chemotherapy induced peripheral neuropathy represents a well-known side effect of platin-based chemotherapy regimens 23 . Up to 90 % of patients are affected after systemic oxaliplatin treatment, and treatment options remain scarce 24 , 25 .…”

Section: Discussionmentioning

confidence: 99%

Inflammatory Response and Toxicity After Pressurized IntraPeritoneal Aerosol Chemotherapy

H¹,

Grass²,

Labgaa³

et al. 2018

J. Cancer

View full text Add to dashboard Cite

Background: Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) is a novel mode of intraperitoneal (IP) drug delivery claiming high IP tissue concentrations with low systemic uptake. The aim was to study inflammatory response and systemic toxicity after PIPAC.Methods: Retrospective monocentric analysis of a consecutive cohort of PIPAC patients between January 2015 and April 2016. Detailed hematological and biochemical analysis was performed the day before surgery and once daily until discharge. Comparative statistics were performed using Mann-Whitney U test and Wilcoxon signed ranked test.Results: Fourty-two consecutive patients underwent a total of 91 PIPAC procedures. Twenty patients received oxaliplatin and 22 cisplatin+doxorubicin (37 vs. 54 procedures). Creatinine, AST and ALT were not significantly altered after PIPAC (p=0.095, p= p=0.153 and p=0.351) and not different between oxaliplatin and cisplatin+doxorubicin regimens (p=0.371, p=0.251 and p=0.288). C-reactive protein (CRP) and procalcitonin (PCT) increased on post-operative day (POD) 2: ∆max 29±5 mg/L (p<0.001) and ∆max 0.05±0.01 μg/L (p=0.005), respectively. Leucocytes increased at POD 1: ∆max 2.2±0.3 G/L (p<0.001). Albumin decreased at POD 2: ∆max -6.0±0.5 g/L (p<0.001). CRP increase correlated positively with Peritoneal Cancer Index (tumor load) (ρ =0.521, p<0.001).Conclusion: PIPAC was followed by a modest and transitory inflammatory response that was commensurate to the disease extent. No hematological, renal or hepatic toxicity was observed even after repetitive administration.

show abstract

Minimizing chemotherapy-induced peripheral neuropathy: preclinical and clinical development of new perspectives

Cited by 29 publications

References 97 publications

New Insights into Potential Prevention and Management Options for Chemotherapy-Induced Peripheral Neuropathy

New Insights into Potential Prevention and Management Options for Chemotherapy-Induced Peripheral Neuropathy

Chemotherapy-induced peripheral neuropathy—part 2: focus on the prevention of oxaliplatin-induced neurotoxicity

Inflammatory Response and Toxicity After Pressurized IntraPeritoneal Aerosol Chemotherapy

Contact Info

Product

Resources

About